Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.

Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology

Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma - ScienceDirect

Molecules, Free Full-Text

In search of effective therapies to overcome resistance to Temozolomide in brain tumours

Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide

PDF) Phase I study of temozolomide in paediatric patients with advanced cancer

A) Sites of alkylation on the various bases in the DNA. Temozolomide

T1178-50mg Temozolomide [85622-93-1] Hexabiogen

Biomedicines, Free Full-Text

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

Temozolomide Cas# 85622-93-1 - GlpBio

Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies